EAST NORRITON, Pa., March 23, 2011 /PRNewswire/ -- Tengion, Inc. (Nasdaq: TNGN), a leader in regenerative medicine, today announced the addition of two renal research and clinical experts, Ben Humphreys, M.D., Ph.D. and Giuseppe Remuzzi, M.D., F.R.C.P., from the Harvard Stem Cell Institute and Mario Negri Institute respectively, to its panel of Research & Development Advisors. This panel provides counsel to Tengion and engages leading researchers, clinicians, and patient advocates with the company as it advances its Organ Regeneration Platform™. The newest additions to the panel will work with Tengion in the area of renal function and chronic kidney disease (CKD) as the Company continues to advance its Neo-Kidney Augment™ program. The Neo-Kidney Augment, which is designed to delay or prevent the need for dialysis or kidney transplantation in patients at risk of chronic kidney failure, has demonstrated consistently positive data that Tengion scientists have published or presented in four different animal models of kidney failure, including in large animals.
"The appointment of these leaders to our advisory panel will provide Tengion with rich insights as we work to advance our Neo-Kidney Augment to clinical trials," said Steven Nichtberger, M.D., President and Chief Executive Officer of Tengion. "There is a great need for new treatments for patients with chronic kidney disease," stated Dr. Remuzzi. "I look forward to helping Tengion identify the most rapid and efficient pathways to clinical trials." Dr. Humphreys added, "The recent preclinical findings for Tengion's Neo-Kidney Augment show that innovative approaches are beginning to offer promising results. I am enthusiastic about working with Tengion to explore these findings and further advance development."
Joining Tengion's panel of Research & Development Advisors are:
|SOURCE Tengion, Inc.|
Copyright©2010 PR Newswire.
All rights reserved